Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant PEG IFN alfa-2b vs Observation in Ulcerated Primary Cutaneous Melanoma
NCT01502696Phase 3Unknown
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2012
- Primary completion
- Apr 2019
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2b in melanoma (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Relapse-free survival at 6.3 years. Status: unknown.
02
Drugs
peginterferon alfa-2b
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01502696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01502696.